Begrivac®

BIOLOGICAL2 trials

Sponsors

Chiltern Pesquisa Clinica Ltda

Conditions

Chronic Heart DiseaseChronic Pulmonary DiseaseDiabetes MellitusH1N1 Influenza VirusHuman Immunodeficiency Virus Type 1 (HIV-1) Infection

Phase 3

Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

CompletedNCT01032395

Chiltern Pesquisa Clinica LtdaChronic Heart Disease, Chronic Pulmonary Disease, Diabetes Mellitus +1

Start: 2010-03-31End: 2012-08-31Updated: 2013-06-14

Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection

CompletedNCT01032408

Chiltern Pesquisa Clinica LtdaH1N1 Influenza Virus, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Start: 2010-04-30End: 2012-07-31Updated: 2013-06-05

Related Papers

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01